

Granzyme B, a novel mediator of allergic inflammation: Its induction and release in blood basophils and human asthma

Cornelia M. Tschopp^{1*}, Nicole Spiegl^{1*}, Svetlana Didichenko^{1*}, Werner Lutmann²,
Peter Julius², J. Christian Virchow², C. Erik Hack³
and Clemens A. Dahinden¹

¹ Institute of Immunology, Inselspital, University of Bern, Switzerland

² Department of Pneumology, University Medical Clinic, Rostock, Germany

³ Sanquin Research at the CLB, Amsterdam, the Netherlands

Short title: Granzyme B in human basophils and asthma

Corresponding author: Clemens A. Dahinden, MD, Institute of Immunology
University Hospital Bern, Inselspital, CH-3010 Bern, Switzerland
Tel: +41-31 632 8244. Fax: +41-31 381 5735
E-Mail: clemens.dahinden@iib.unibe.ch

*These authors contributed equally to this work.

³Present address: Crucell, Leiden, the Netherlands

This study was supported by the Swiss National Science Foundation grant 3200-063550 and 3200B0-105843 (CAD), by the Stiftung 3R (SD) and the Deutsche Forschungsgemeinschaft Vi 193/3-1 (JCV). The authors have no conflicting financial interests.

Contributions of the authors:

CMT, NS, SD: Designed, performed and analyzed experiments

CEH: Contributed essential analytical tools. WL, PJ, JCV: provided BAL samples and clinical data of asthmatic patients. CAD: Design and presentation of the study.

Abstract

Histamine, leukotriene-C₄, IL-4 and IL-13 are major mediators of allergy and asthma. They are all formed by basophils and are released in particularly large quantities after stimulation with IL-3. Here we show that supernatants of activated mast cells or IL-3 qualitatively change the make-up of granules of human basophils by inducing *de-novo* synthesis of granzyme B (GzmB), without induction of other granule proteins expressed by cytotoxic lymphocytes (granzyme A, perforin). This bioactivity of IL-3 is not shared by other cytokines known to regulate the function of basophils or lymphocytes. The IL-3 effect is restricted to basophil granulocytes as no constitutive or inducible expression of GzmB is detected in eosinophils or neutrophils. GzmB is induced within 6-24 hours, sorted into the granule compartment, and released by exocytosis upon IgE-dependent and –independent activation. *In vitro*, there is a close parallelism between GzmB, IL-13 and leukotriene-C₄ production. *In vivo*, Granzyme B, but not the lymphoid granule marker granzyme A, is released 18 hours after allergen challenge of asthmatic patients in strong correlation with interleukin-13. Our study demonstrates an unexpected plasticity of the granule composition of mature basophils and suggests a role of granzyme B as a novel mediator of allergic diseases.

Introduction

The incidence of allergic diseases, such as asthma, has reached epidemic proportions in industrialized countries representing a major public health problem and economic burden¹⁻³. The pathophysiology leading to bronchial hyperreactivity, mucus secretion and tissue remodeling involves complex interactions between resident cells and leukocytes attracted at sites of inflammation^{2,3}. Local allergen provocation of allergic patients has been most useful in studying the timed events of these interactions in vivo, leading to the conclusion that the so-called late-phase reaction occurring hours after allergen exposure is most relevant for the symptoms in allergic diseases. Most studies and reviews have focused on the roles of T-cells and eosinophils^{2,3}, although 20 years ago an important involvement of basophils has been postulated based on the distinct mediator profile found immediately and late after allergen exposure⁴. Indeed, more recent studies using an antibody specific for basophil granules showed that basophils rapidly infiltrate the challenged tissue^{5,6}. Thus, basophil granulocytes should be considered as key effector cells in Th2-type immune responses and allergic inflammation⁷⁻⁹. Human basophils are also a prominent source of the mediators histamine and leukotriene C₄ (LTC₄)¹⁰, and the cytokines IL-4 and IL-13¹¹⁻¹⁵, all major players in asthma. Like mast cells, they express high-affinity IgE-receptors and harbor histamine in their granules. We and others, however, showed that they are more closely related to eosinophils since they share many receptors for cytokines and chemokines (e.g. eotaxin-receptors, CCR3), indicating similarities in their trafficking and modes of activation^{15,16}. In murine immunology, the function of basophil-like cells has been similarly neglected¹⁷, although IL-4 producing FcεRI+ non-B/non-T cells were described 10 years ago¹⁸. However, several recent studies now document the importance of murine basophils in Th2-type immune responses and chronic allergic inflammation¹⁹⁻²¹.

In contrast to other granulated leukocytes, little is known about the make-up of basophil granules. The composition of granule proteins and regulation of their expression has been most thoroughly studied in neutrophils²²⁻²⁴. Developing neutrophils undergo a timed program of expression and packing of granule proteins for primary, secondary and tertiary granules. It is thus generally assumed that the composition of granule proteins of mature granulocytes is fixed once these cells leave the bone-marrow^{22,23}.

The effector functions of human basophils are strongly enhanced by IL-3, IL-5, GM-CSF and nerve growth factor (NGF)^{10,25-27}. These cytokines are released by T-cells and mast cells (MCs) and are thus found at sites of allergic inflammation^{2,3,28,29}. Among them, IL-3 is the most potent priming cytokine of basophils and the major regulator of IL-4 and IL-13 expression^{10,11,13-15,25}. Furthermore, IL-3 has the longest duration of action and can also induce phenotypic alterations of mature basophils^{12,15,30-32}.

Addressing the question whether cytokines may affect the composition of basophil granules, we found that IL-3 strongly induces mRNA for granzyme B (GzmB), a 28 kDa serine protease thought to be restricted to the lymphoid lineage which is a major effector of granule-mediated cytotoxicity³³. IL-3 selectively promotes *de-novo* expression of GzmB-protein in human basophils, but not in other granulocyte-types. *In vitro*, GzmB is induced in basophils in parallel with IL-13, and both mediators are found *in vivo* in a highly correlated manner in the lavage fluids in allergic late-phase reactions after segmental allergen challenge of asthmatic patients. Thus, GzmB must be considered as a novel basophil-derived mediator of allergic inflammation.

Results

IL-3 induces granzyme B in mature blood basophils without detectable granzyme A and perforin

IL-3 promotes a rapid, strong (of three to four orders of magnitude) and reversible induction of GzmB mRNA in human basophils, as determined by TacMan quantitative RT-PCR (Table 1). On the level of the induction of GzmB protein, IL-3 shows a threshold effect at 0.3 ng/ml, an ED50 of 1-3 ng/ml and a plateau reached at 10 ng/ml, as determined by GzmB ELISA and western blotting of cell lysates (Fig. 1A; for variability of GzmB expression see (Supplementary Fig. 1). No GzmB was detected in basophils cultured in medium (Fig. 1A/B), with the exception of rare cases in which a slight induction became detectable (see figures 4C and 5). As a positive control, lysates of NK-cells were included in the blots indicating that the GzmB content of IL-3-treated basophils approximates that found in NK-cells (Fig. 1B). In contradiction with a recent report³⁴, no GzmB was detected in neutrophils. To further compare the composition of granule constituents in basophils, neutrophils and NK-cells, we performed immuno-blots for neutrophil α -defensin-1/3 (HNP-1/3). As expected²²⁻²⁴, neutrophils contain high levels of HNP-1/3, in contrast to lower levels found in basophils which are unaffected by IL-3, and NK-cells which lack this peptide.

In order to examine the induction of GzmB at the population level, we used intracellular staining of GzmB analyzed by flow-cytometry. The data in figure 1C confirm the induction of GzmB by IL-3 and also show a broad distribution in the intensity of staining, indicating some heterogeneity in the capacity of basophils to express this enzyme. Searching for other markers that are up-regulated by IL-3 we identified ST2, an IL-1 receptor family member involved in Th2 responses which is preferentially expressed in murine Th2 cells³⁵⁻³⁷. Figure 1C shows an IL-3-induced up-regulation of ST2 resulting in a parallel shift of the entire basophil population indicating that basophils are able respond to IL-3 in a uniform manner. Examination of GzmB subcellular localization by immuno-fluorescence microscopy revealed

its granular cytoplasmic distribution (Fig. 1D), consistent with the hypothesis that this protein is sorted to the granule compartment.

Expression of two other granule constituents of cytotoxic lymphocytes³³, Granzyme A (GzmA) and perforin, was not detectable in basophils cultured without or with IL-3. Using several experimental approaches including flow cytometry and GzmA ELISA, no intracellular GzmA was observed in basophils above the limits of the assays (<100 pg/10⁶ basophils), while blood NK-cells and, NK-92 cells, a human activated NK-cell line, contained even higher levels of GzmA than GzmB. Furthermore, no signal for perforin was detected by flow cytometry and western blotting, in contrast to NK-cells serving as positive controls. No GzmA, GzmB and perforin could be detected in neutrophils (data not shown).

The time course of the induction of GzmB by IL-3 was examined in basophils by flow-cytometry, western-blotting (not shown) and by GzmB ELISA (Figures 2A; and 3). GzmB was detectable after a lag period of six hours, most strongly increased between 10 and 18 hours and reached a plateau at about 24 hours.

Induced granzyme B is sorted into basophil granules and can be released in response to IgE-dependent and –independent agonists

The best evidence for sorting of GzmB into the granule compartment implies the demonstration of its release upon degranulation together with other basophil granule components, such as histamine. We thus triggered exocytosis of basophils with two potent stimuli which utilize distinct types of receptors and signaling pathways, with anti-Fc ϵ RI α to cross-link IgE-receptors or with C5a to activate the G-protein-coupled receptor CD88. Cells were incubated for various time intervals without or with IL-3 before inducing degranulation, followed by measurements of cell-free and cell-associated histamine and GzmB (Fig. 2A). Indeed, GzmB was released in response to both stimuli and the relative proportion which was mobilized appeared to increase with the time, consistent with a time-dependent sorting

into the granule compartment following induction and synthesis. Release of GzmB by IL-3-primed basophils was also induced by another strong agonist, fMLP, and by weaker agonists, MCP-1, a ligand of CCR2³⁸, and eotaxin, a selective agonist of CCR3¹⁶, together with histamine release and leukotriene C₄ (LTC₄) formation (Fig. 2B).

Continuous granule exocytosis, granzyme B secretion, LTC₄ formation and cytokine production induced by C5a and IL-3

We previously showed, that acute priming of basophils by IL-3 permitting C5a-induced lipid mediator release and enhancing degranulation requires a preincubation with IL-3 for 5 min or more, while no effect was observed when the order of the stimuli was reversed¹⁰. However, prolonged culture of blood basophils with a combination of C5a and IL-3 leads to continuous formation of LTC₄ in parallel with the expression and release of high levels of IL-4 and IL-13, a phenomenon that does not depend on the order of the stimuli added, but requires, apart from the presence of IL-3, ongoing signaling through the C5a receptor^{13-15,39}. This model of a late-phase response was now used to investigate the expression and/or release of GzmB, together with histamine, LTC₄, IL-4 and IL-13. In order to minimize the anaphylactic exocytosis of histamine in response to a bolus of C5a at 37° C, this agonist was added on ice just before culture at 37°C. Figure 3 shows that this alteration in stimulus addition did not affect the regulation of IL-4/IL-13 release and LTC₄ formation reported previously¹⁴. Interestingly, the combined action of C5a and IL-3 also leads to a slow late-phase of degranulation as evidenced by the secretion of histamine during 3 to 23 hours in parallel with IL-4/IL-13 expression. IL-3 does not require the cooperation of C5a to optimally induce GzmB, and C5a does neither directly promote nor alter IL-3-induced GzmB expression, as evidenced by the sum of the cell-free and cell-associated product. However, culture of basophils in the presence of C5a plus IL-3 results in an enhanced protracted release of GzmB, indicating concomitant sorting and release through the granule compartment.

Induction of granzyme B expression by cytokines and supernatants of IgE-activated mast cells

We next tested the ability of several cytokines to induce the expression of GzmB in human basophils (Fig. 4A). We chose four growth factors, IL-3, IL-5, GM-CSF and NGF, which all acutely prime basophils with similar efficacy^{10,25,26}, as well as cytokines thought to enhance cytotoxic functions of lymphocytes (IL-2, interferon- α and interferon- γ). The efficacy of IL-3 to induce GzmB was rather unique since only weak effects were observed in response to other basophil-priming cytokines. Interestingly, "late priming" for C5a-induced LTC₄ formation^{31,32} and the induction of GzmB expression shows an identical pattern and order of efficacy of the cytokines (IL-3>>>NGF>IL-5>GM-CSF), while IL-3 and NGF were similarly effective in enhancing C5a-induced degranulation. A similar pattern of responses was found using different doses of IL-3. The dose-response relationship between GzmB expression and facilitation of lipid mediator formation was identical (ED50: 1-3 ng/ml), while lower doses of IL-3 were sufficient to enhance degranulation (ED50: 0.1-0.3 ng/ml) (Fig. 4B). Thus, these data together with our earlier studies on IL-4 and IL-13 expression^{11,13-15,39} demonstrate a close conditional and temporal relationship between the induction of granzyme B, the facilitation of C5a-induced LTC₄ formation, and the promotion of IL-4 and IL-13 production.

In order to mimic the molecular and cellular events of allergic late-phase reactions, basophils were exposed to supernatants of mature human mast cells (MCs) cultured for 24 h with or without activation by Fc ϵ RI α -crosslinking. Similar to IL-3, the products of activated MCs induced the expression GzmB mRNA (induction by 3-4 orders of magnitude after 6 hours;) as well as GzmB protein (Fig. 4C). MC-induced GzmB expression in basophils could be inhibited by a neutralizing polyclonal anti-IL-3 antibody, indicating that the effect is largely due to MC-derived IL-3 formed in response to IgE-receptor activation. Because among close to 20 cytokines studied, only IL-3 induced sustained Tyr694-phosphorylation of Stat5 in human basophils (our unpublished findings), this parameter was also examined. The enhanced Stat5 phosphorylation in response to the products of activated MCs and its

inhibition by IL-3 neutralization further demonstrates the key role of IL-3 in this model of MC-basophil interaction.

Granulocyte type restricted induction of granzyme B

IL-3 belongs to a subgroup of growth-factors (IL-3, IL-5, GM-CSF) which share a common receptor beta-chain (CD131) needed for signaling^{40,41}. Neutrophils express GM-CSF receptors only, while eosinophils express receptors for all three cytokines⁴⁰. Thus, we examined whether appropriate cytokines are able to induce GzmB expression in other types of granulocytes. In marked contrast to basophils, none of the growth factors stimulated GzmB expression in neutrophils and eosinophils (Fig. 5). In comparison, a different pattern of expression of another protein, Pim-1, was observed in all types of granulocytes, confirming cellular responsiveness to stimulation (Fig. 5B). Pim-1 is a serine/threonine kinase induced by growth/survival factors in hematopoietic cells, and IL-5 and GM-CSF was shown to stimulate Pim-1 mRNA and protein expression in human eosinophils^{42,43}. The induction of Pim-1 expression by cytokines interacting with CD131 in all granulocytes further underscores the unique ability of basophils to express GzmB, suggesting a cell-specific function for this protein.

NK-like cytotoxicity activity of human basophils

To assess a possible functional role of GzmB, we tested whether basophils can mediate lysis of appropriate target cells. Because basophils express high levels of CD244, we used the B-cell line 721.221 which expresses CD48, the ligand for CD244, as target cells in the cytotoxicity assay^{44,45}. Figure 6 shows that basophils indeed display NK-like activity towards these target cells, albeit less strongly than NK-cells. Basophil-mediated target cell lysis is completely blocked by the pan-caspase inhibitor Z-VAD consistent with a caspase-dependent killing mechanism. Importantly, the cytotoxic activity of basophils is considerably enhanced by IL-3 and can be inhibited by the GzmB-inhibitor Z-IETD, suggesting an involvement of GzmB in the cytolytic activity of IL-3 treated basophils.

Release of Granzyme B in vivo after experimental allergen challenge of asthmatic patients

In humans, basophils rapidly infiltrate affected tissues and may then be activated by endogenous cell-derived and humoral agonists to release inflammatory mediators and cytokines. If basophils are activated to express and release GzmB in vivo, one would expect GrzmB release within the allergic late-phase reaction (LPR). Segmental allergen challenge is a particularly elegant model, since only one lung segment is challenged with allergen while a control segment is challenged with vehicle²⁸. Thus, each patient serves as his own control. We measured GzmB levels in bronchiolar-alveolar lavage (BAL) fluids obtained 10 minutes and 18 hours after segmental challenge with solvent and allergen of 13 patients with allergic asthma. Tryptase was measured as a MC degranulation marker and GzmA as a marker of cytotoxic granules from lymphocytes. IL-13 levels were determined, because IL-13 is regarded as a key cytokine in the pathogenesis of asthma⁴⁶, and because both mediators are induced in basophils in a similar manner and within the same time-frame. Figure 7A demonstrates that, indeed, GzmB and IL-13 levels, in contrast to GzmA, were increased in BAL-fluids of challenged segments after 18 hours in almost all patients, but not in the controls. In contrast to all other parameters, tryptase was increased 10 min after allergen exposure, indicating that mast cell do not release preformed GzmB. Mean GzmB concentrations were about seven times higher than those of IL-13 and the increase of both mediators was highly significant ($p < 0.0001$ between groups by ANOVA; see [Supplementary Fig.2](#)). Particularly striking for clinical human samples is the excellent correlation between IL-13 and GrzmB levels found 18 hours after challenge, in contrast to the lack of significant correlations between IL-13 and GzmA, between GzmB and GzmA, or between immediate tryptase and late GzmB levels (Fig. 7B). The increase of IL-13 and GzmB was less consistent and pronounced 42 hours and was absent 162 hours after allergen provocation as examined in 6 and 4 patients, respectively ([Supplementary Fig.3](#)). Thus, IL-13 and GzmB appear in the LPR in a highly related manner and within the same time frame.

Discussion

This study demonstrates that IL-3 can qualitatively alter the composition of granule constituents of mature human blood basophils by inducing *de-novo* expression of GzmB. More preliminary data indicate that the expression of some other granule proteins may also change depending on the cytokine milieu, a further sign of the remarkable plasticity of granule protein expression of this blood granulocyte type. Thus, the notion that the granule components of blood granulocytes have a fixed cell type-dependent composition must be revised, at least for basophil granulocytes. The induction of GzmB in basophils is particularly surprising because, within the immune system, GzmB is thought to be restricted to the lymphoid lineage^{33,47,48}. Up to date, there has been no indication that myeloid cells may express GzmB, with the exception of a report claiming the presence of GzmB and perforin in human blood neutrophils³⁴. This view has been refuted by several groups⁴⁹⁻⁵¹ and is also in conflict with our data. Even eosinophils, cell closely related to basophils, do not express GzmB constitutively or after stimulation with IL-3, IL-5 or GM-CSF, demonstrating the importance of the cellular background and indicating that some gene(s) expressed by basophils are needed for IL-3 induced GzmB expression.

Functional experiments with different triggers conclusively demonstrate that GzmB is sorted, at least in part, to a granule compartment which can be mobilized in a way similar to histamine, although the extent of exocytosis of these mediators does not fully overlap. Using experimental conditions resulting in the expression of high levels of IL-4 and IL-13 together with a prolonged wave of LTC₄ formation, we found that the combination of C5a and IL-3 leads to a slow secretion of GzmB in parallel with its formation. C5a neither directly induces GzmB nor alters the amounts or kinetics of IL-3-induced GzmB production. Thus, the regulation of GzmB expression in basophils differs from that of IL-4/IL-13 which need both signals for optimal induction, and also from that of plasminogen activator inhibitor-1 which is induced by C5a alone⁵².

In allergic late-phase reactions infiltrating basophils must be activated by endogenous agonists, although activation by allergen may also play a role in chronic disease. Our previous and the present studies, therefore, focused on the effects of endogenous stimuli either alone or in combination. Particularly striking is the close correlation between leukotriene formation, IL-4 and IL-13 expression and the *de-novo* induction of GzmB, with regards to both the time frame and the efficacy of cytokines regulating these important functions in basophils: The most efficient cytokine inducing GzmB together with other phenotypic and functional alterations is IL-3³⁰⁻³². An identical concentration range of IL-3 induces GzmB expression and the persistent facilitation of LTC₄ formation. When the effect of different cytokines was compared we observed an identical order of efficacy. The same is true for the regulation of IL-4 and IL-13 expression, as shown earlier^{13-15,39}. The fact that supernatants of IgE-receptor-activated human MCs can induce GzmB expression in blood basophils further supports the pathophysiological relevance of our observations. Although this induction of GzmB is largely due to MC-derived IL-3, other mast cell cytokines may also contribute.

In agreement with these *in vitro* findings and further supporting a role of basophils in human asthma, we found a highly correlated increase of IL-13 and GzmB levels in the BAL-fluids of the challenged lung-segment of patients with allergic asthma 18 hours after provocation. Thus, GzmB must be considered as a potential mediator of asthma, apart from its well established role in granule-mediated cytotoxicity of lymphocytes. There is increasing evidence that IL-13 is a key cytokine in promoting the clinical symptoms of asthma, such as bronchial hyperreactivity and mucus secretion. It is, therefore, reasonable to assume that the level of IL-13 after allergen provocation is an indicator for the severity of the local LPR. The excellent correlation between IL-13 and GzmB in the challenged segments at 18 hours together with the lack of a significant correlation between these GzmB levels and tryptase released in the immediate reaction indicates that GzmB levels reflect the intensity of the

LPR. Importantly, GzmB was released without an increase of GzmA during this time-point of the LPR, data consistent with a non-lymphoid source of this protease since cytotoxic lymphocytes (CLs) express even larger amounts of GzmA than GzmB. Indeed, in BAL-fluids of patients with CD8+T-cell-mediated hypersensitivity pneumonitis higher levels of GzmA than GzmB are found⁵³. Furthermore, human NK-92 cells express similar amounts of GzmB as stimulated basophils, but about 2-3 times more GzmA. Finally, although T-cells may selectively express GzmB under some circumstances (*in vitro* stimulation with anti-CD3+anti-CD46)⁵⁴, we never observed even a minor population of GzmA-/GzmB+ cells in the T-cell compartment *in vivo*, in contrast to GzmA+/GzmB+ and GzmA+/GzmB- subpopulations⁴⁷. Taken together, our *in vitro* and *in vivo* data strongly suggest that basophils are a source of GzmB found at sites of allergic inflammation, although one cannot exclude a contribution of other cells selectively expressing GzmB, such as plasmacytoid dendritic cells. Furthermore, our study does not exclude a (most probably minor) contribution of lymphocyte-derived GzmB, particularly at later time points after challenge when GzmB levels are decreasing and lymphocyte accumulation becomes more prominent, since a small proportion of BAL lymphocytes have been shown to express GzmB⁵⁵. It should be noted, however, that the percentage of granzyme expressing lymphocytes does not change 42 hours after allergen challenge⁵⁵.

The function of GzmB has been thoroughly studied for its involvement in granule-mediated cytotoxicity. In CLs, perforin is needed to deliver GzmB into the cytosol thereby inducing apoptosis of target cells³³. In order to find a possible functional role of GzmB induction in basophils, we tested whether basophils may be able to kill appropriate target cells, although they are not regarded as killer cells and do not express detectable perforin. Surprisingly, we find an NK-like activity which is enhanced by IL-3 and diminished by GzmB-inhibition, challenging this dogma and indicating a perforin-independent unknown killing mechanism which needs further investigation. It should be noted that membrane-active bacterial toxins and adenovirus can substitute for perforin⁵⁶, and it is thus not impossible that a myeloid

granule component present in basophils, but not lymphocytes, may similarly substitute perforin. Furthermore, a perforin-independent GzmB-dependent cytotoxicity has been very recently suggested for murine T-regulatory cells⁵⁷. However, in asthma an extracellular role of GzmB is much more likely, since GzmB is readily released by basophils and since this protease is less inhibited by anti-proteases in bodily fluids⁵³ than other cell-derived enzymes. Furthermore, outside the immune system, GzmB is produced in the absence of perforin by cells of the reproductive system further indicating bioactivity of GzmB unrelated to target-cell lysis⁵⁸. Unfortunately, and in contrast to intracellular proteins, possible extracellular GzmB substrates are only beginning to be investigated. Most relevant for this hypothesis is a very recent report demonstrating extracellular matrix remodeling by GzmB with induction of death in adherent cells by cell-detachment (anoikis)⁵⁹. Thus, GzmB released in asthma could play a role in tissue remodeling.

In conclusion, our study demonstrates that IL-3 not only alters the function of mature blood basophils but also leads to a qualitative change of the composition of their granules by *de-novo* expression of GzmB. There is a close conditional and temporal correlation between GzmB and IL-13 secretion by basophils *in vitro* and during the allergic late-phase reaction in patients with asthma *in vivo*, indicating an unsuspected novel role of basophil-derived GzmB in the pathogenesis of allergic inflammation and possibly other Th2-type immune responses, such as the defense against helminth parasites.

Materials and Methods

Cell stimuli

The complement product C5a was purified from yeast-activated human serum¹⁰. Anti-Fc ϵ RI α mAb 29C6, directed against the non-IgE-binding epitope of the high-affinity IgE-receptor α -chain was from Roche (Nutley, NJ). fMLP (Novabiochem, Switzerland), rhMCP-1, rhEotaxin-1 and rhNGF (Preprotech, London, England), and rhIL-2 (BD Biosciences, Switzerland) were purchased from commercial sources. rhIFN- α , rhIFN- γ , rhIL-5 were provided by Roche (Basel, Switzerland) and rhGM-CSF, rhIL-3 by Novartis (Basel, Switzerland).

Leukocyte isolation and purification

Basophils¹⁴, eosinophils and neutrophils were purified from peripheral blood of healthy adult volunteers. Briefly, venous EDTA-blood (180 ml) was collected and left to sediment in 6% dextran (Amersham, Biosciences). Leukocytes were enriched for basophils using a two-step discontinuous Percoll gradient (1.0791 and 1.0695 g/ml; Amersham, Biosciences) and further purified by negative selection using MACS basophil isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of isolated basophils ranged between 95 and 99%. Following basophil depletion, remaining granulocytes (pellet fraction) were separated using a single-step Percoll gradient (1.0915 g/ml). Neutrophils and enriched eosinophils collected at the interphase and in the pellet, respectively, were subjected to erythrocyte lysis. Purified neutrophils were scarcely contaminated (<2%) with eosinophils. Eosinophils were further purified to >95% by negative selection using anti-CD16 and anti-glycophorin A magnetic beads (both from Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of isolated granulocytes was assessed by Gimsa staining.

NK-cells were purified from peripheral blood mononuclear cells (PBMC) using a negative selection kit according to the manufacturer's protocol (NK-Cell Isolation Kit-II, Miltenyi Biotec, Bergisch Gladbach, Germany).

Cell culture and mediator release measurements.

Granulocytes were cultured in complete culture medium [RPMI-1640 supplemented with 2mM L-glutamine, 25mM HEPES, pH7.4, (Gibco, Invitrogen), 10% heat-inactivated FCS (Seromed, Switzerland) and antibiotics (100IU/ml penicillin, 100µg/ml streptomycin;)]. For release experiments, basophils (0.2×10^6 cells in 200µl) were cultured in 96-well U-bottom tissue-culture plates at 37°C, 5%CO₂. Following stimulation, cells were collected by centrifugation. Cell pellets were lysed by snap-freezing and thawing in the original volume of medium. Cell-lysates and supernatants were further used for the measurements of mediators, cytokines and granzymes.

Tryptase was measured with the ImmunoCAP analyser and reagents from Phadia (Uppsala, Sweden). IL-4 and IL-13 were measured by ELISA (Eli-pair kit, Diaclone, Besançon, France) according to manufacturer's protocols. GzmA and GzmB production were measured by ELISA, as described⁵³. Histamine and LTC₄ were measured by fluorometry and RIA, respectively²⁶.

Culture of basophils with supernatants of human mast cells

Human mast cells were isolated from intestinal tissue obtained from healthy sections after surgery of tumour patients as described²⁹. After purification using positive selection with anti-c-Kit-coated magnetic beads (Miltenyi Biotec), mast cells were cultured for 10 days with 100ng/ml SCF followed by two weeks with 20ng/ml IL-4 + 100ng/ml SCF. Before the collection of supernatants, mast cells (>99% purity) were washed, suspended at 1×10^6 cells/ml in fresh medium containing SCF only, and cultured for 24 h with or without 100ng/ml anti-FcεRIα mAb. Supernatants were centrifuged through a Biomax 100K membrane (Millipore) to remove any residual anti-FcεRIα mAb and added in a 1:1 dilution to basophils (3.6×10^6 cells/ml) in fresh medium. Where indicated, mast cell supernatants were pre-incubated for 10 min with 10 µg/ml anti-IL-3 antibody (affinity-purified goat anti-human IL-3; R&D).

Flow cytometry

For intracellular staining, cells were fixed and permeabilized using the Fix-and-Perm Cell Permeabilization kit (Caltag). Cells were re-suspended in PBS supplemented with 5% FCS and stained with fluorochrom-labeled mAbs: anti-GzmB-PE (mIgG1, clone GB11; Serotec), anti-GzmA-FITC (mIgG1, clone CB9), anti-perforin-FITC (mIgG2b, clone δ G9), or isotype control mAbs (mIgG1, clone MOPC-21; mIgG2b, clone 27-35) (all from BD-Biosciences). For surface staining, basophils were incubated with anti-hST2 mAb (IgG1, clone B12; MBL) or control mAb (mIgG1, clone 107.3; BD-Biosciences) in PBS supplemented with 10% donor serum, followed by goat-anti-mouse IgG PE-F(ab')₂ (Serotec). Flow cytometry was performed with a FACSCalibur (BD-Biosciences). At least 5×10^4 events were acquired.

Western blot analysis

Proteins were precipitated out of the cell suspension with 10% trichloroacetic acid, separated in NuPAGE 12% Bis-Tris gels (20 μ g of protein per line) and transferred to PVDF membranes (Invitrolon, Invitrogen). Antibodies used for the detection were: anti-GzmB mAb (GB-4)⁵³, anti-Pim1 mAb (sc-13513; Santa Cruz Biotechnology) rabbit anti-P-Stat5(Tyr694) (9351; Cell Signaling) and anti- α -defensin HNP-1/3 mAb (Serotec). Secondary HRP-labeled goat anti-mouse and goat anti-rabbit antibodies were from Bio-Rad. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL-Kit, Amersham). For loading controls, stripped membranes were incubated with an anti- β -actin mAb (clone AC-15; Sigma).

Granzyme B mRNA measurements by RT-PCR

Total RNA was prepared from freshly isolated and cultured basophils using RNeasy-Kit (Qiagen). To generate cDNA, RNA was transcribed by SuperScript II RNase H⁻Reverse Transcriptase (Invitrogen). Random hexamer primers, first strand buffer and DTT were from Invitrogen, PCR Nucleotide Mix and RNasin from Promega (Catalysis). Real-time PCR was

carried out using commercially pre-designed primers and probes for GzmB (Hs00188051_m1) and PBGD (Hs00609297_m1) (Applied Biosystems). PCR was run on an ABI prism 7700 sequence detector using universal cycling conditions and data were analyzed using the Sequence Detector software from Applied Biosystems. The amount of GzmB-mRNA, normalized to an endogenous reference (PBGD) and relative to a calibrator (freshly isolated basophils), is given by $2^{-\Delta\Delta Ct}$ and designated as fold change.

Immunofluorescence

Cytospin preparations of basophils were fixed with 1.33% paraformaldehyde in saturated aqueous picric acid for 10min, washed with PBS and blocked in TBS/PBS (1:1) containing 1% goat serum for 1h. Incubation with anti-GzmB mAb (20 μ g/ml, IgG1, Hoelzel Diagnostika, Germany) or isotype control mAb (20 μ g/ml, IgG1; BD-Biosciences) followed by a goat anti-mouse IgG Alexa-FluorTM 488-conjugated F(ab')₂ (Molecular Probes; 1 to 1000 dilution). DNA was stained with DAPI (1 μ g/ml; Fluka). Images were acquired and analyzed using constant settings on a Nikon Eclipse E600 fluorescence microscope with a 60x oil objective using FITC and DAPI filter sets.

Cytotoxicity assay

⁵¹Chromium release cytotoxic assay was performed against the MHC-I deficient, human B-lymphoblastoid cell line 721.221^{44,45}. Briefly, 721.221 cells were labeled with Na₂⁵¹CrO₄ (100 μ Ci/10⁶ cells; Amersham, Switzerland) for 1h at 37°C. Target cells were washed and seeded on U-bottom 96-well plates at 2.000 cells per well in 100 μ l. Effector cells (basophils or NK-92 cells)⁴⁴ were then added in 100 μ l medium at an effector:target ratio of 15:1, 30:1 and 60:1 and cultured during 10h. Control wells for spontaneous chromium release contained 2.000 labeled and 20.000 unlabeled target cells in 200 μ l per well. Maximum ⁵¹Cr release was determined in target cells lysed with 0.5% Triton X-100. The cytotoxicity was estimated as percentage of cell lysis according to the formula: cell lysis % = [(experimental release – spontaneous release)/(maximum release–spontaneous release)] x 100. Z-VAD-fmk (z-Val-

Ala-DL-Asp(OMe)-fluoromethylketone) and Z-IETD-fmk (z-Ile-Glu(OMe)-Thr-DL-Asp(OMe)-fluoromethylketone) (BACHEM) were used at concentrations of 50 μ M.

Segmental allergen provocation of allergic patients with asthma and bronchoalveolar lavage (BAL) analysis

For details see [Supplementary Table 1](#). Briefly, segmental allergen provocation was performed in 23 patients in separate lung segments with saline and the relevant allergen, respectively²⁸. In all the patients BAL was performed separately in the allergen- and saline-challenged segments 10min after challenge and BAL-fluids were recovered. Bronchoscopy and BAL were repeated after 18h in 13 patients, or after 48h in 6 patients and after 162h in 4 patients. BAL-fluids were stored at -70°C until analysis. For quantitative measurements of the mediators by ELISA, the BAL-fluids were concentrated by centrifugation using tubes with 5000KD cut-off filters and each concentration factor was calculated by weight determinations. After ELISA, these values were then used to calculate the original BAL-concentration of GzmB, GzmA and IL-13. Approval was obtained from the University Hospital Bern and University Klinikum Rostock institutional review boards for these studies. Informed consent was provided according to the Declaration of Helsinki.

Acknowledgements

We express our sincere thanks to Philippe Demougin, Nicolas Leupin, Michel Bellis and Rodoljub Pavlovic for help and technical assistance.

References

1. Holgate, S.T. 2004. The epidemic of asthma and allergy. *J R Soc Med* 97:103-110.
2. Maddox, L., and D.A. Schwartz. 2002. The pathophysiology of asthma. *Annu Rev Med* 53:477-498.
3. Busse, W.W., and R.F. Lemanske, Jr. 2001. Asthma. *N Engl J Med* 344:350-362.
4. Naclerio, R.M., D. Proud, A.G. Togias, N.F. Adkinson, Jr., D.A. Meyers, A. Kagey-Sobotka, M. Plaut, P.S. Norman, and L.M. Lichtenstein. 1985. Inflammatory mediators in late antigen-induced rhinitis. *N Engl J Med* 313:65-70.
5. Braunstahl, G.J., S.E. Overbeek, W.J. Fokkens, A. Kleinjan, A.R. McEuen, A.F. Walls, H.C. Hoogsteden, and J.B. Prins. 2001. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. *Am J Respir Crit Care Med* 164:858-865.
6. KleinJan, A., A.R. McEuen, M.D. Dijkstra, M.G. Buckley, A.F. Walls, and W.J. Fokkens. 2000. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. *J Allergy Clin Immunol* 106:677-686.
7. MacGlashan, D., Jr., G. Gauvreau, and J.T. Schroeder. 2002. Basophils in airway disease. *Curr Allergy Asthma Rep* 2:126-132.
8. Buckley, M.G., A.R. McEuen, and A.F. Walls. 2002. The return of the basophil. *Clin Exp Allergy* 32:8-10.
9. Falcone, F.H., H. Haas, and B.F. Gibbs. 2000. The human basophil: a new appreciation of its role in immune responses. *Blood* 96:4028-4038.
10. Kurimoto, Y., A.L. de Weck, and C.A. Dahinden. 1989. Interleukin 3-dependent mediator release in basophils triggered by C5a. *J Exp Med* 170:467-479.
11. Brunner, T., C.H. Heusser, and C.A. Dahinden. 1993. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. *J Exp Med* 177:605-611.
12. Schroeder, J.T., D.W. MacGlashan, Jr., A. Kagey-Sobotka, J.M. White, and L.M. Lichtenstein. 1994. IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. *J Immunol* 153:1808-1817.
13. Ochensberger, B., S. Rihs, T. Brunner, and C.A. Dahinden. 1995. IgE-independent interleukin-4 expression and induction of a late phase of leukotriene C4 formation in human blood basophils. *Blood* 86:4039-4049.
14. Ochensberger, B., G.C. Daepf, S. Rihs, and C.A. Dahinden. 1996. Human blood basophils produce interleukin-13 in response to IgE-receptor-dependent and -independent activation. *Blood* 88:3028-3037.
15. Ochensberger, B., L. Tassera, D. Bifrare, S. Rihs, and C.A. Dahinden. 1999. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. *Eur J Immunol* 29:11-22.
16. Uguccioni, M., C.R. Mackay, B. Ochensberger, P. Loetscher, S. Rhihs, G.J. LaRosa, P. Rao, P.D. Ponath, M. Baggiolini, and C.A. Dahinden. 1997. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. *J Clin Invest* 100:1137-1143.
17. Dvorak, A.M. 2000. The mouse basophil, a rare and rarely recognized granulocyte. *Blood* 96:1616-1617.
18. Aoki, I., C. Kinzer, A. Shirai, W.E. Paul, and D.M. Klinman. 1995. IgE receptor-positive non-B/non-T cells dominate the production of interleukin 4 and interleukin 6 in immunized mice. *Proc Natl Acad Sci U S A* 92:2534-2538.
19. Mukai, K., K. Matsuoka, C. Taya, H. Suzuki, H. Yokozeki, K. Nishioka, K. Hirokawa, M. Etori, M. Yamashita, T. Kubota, Y. Minegishi, H. Yonekawa, and H. Karasuyama. 2005. Basophils Play a Critical Role in the Development of IgE-

- Mediated Chronic Allergic Inflammation Independently of T Cells and Mast Cells. *Immunity* 23:191-202.
20. Voehringer, D., K. Shinkai, and R.M. Locksley. 2004. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. *Immunity* 20:267-277.
 21. Min, B., M. Prout, J. Hu-Li, J. Zhu, D. Jankovic, E.S. Morgan, J.F. Urban, Jr., A.M. Dvorak, F.D. Finkelman, G. LeGros, and W.E. Paul. 2004. Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. *J Exp Med* 200:507-517.
 22. Gullberg, U., N. Bengtsson, E. Bulow, D. Garwicz, A. Lindmark, and I. Olsson. 1999. Processing and targeting of granule proteins in human neutrophils. *J Immunol Methods* 232:201-210.
 23. Borregaard, N., and J.B. Cowland. 1997. Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood* 89:3503-3521.
 24. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol* 3:710-720.
 25. Bischoff, S.C., T. Brunner, A.L. De Weck, and C.A. Dahinden. 1990. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. *J Exp Med* 172:1577-1582.
 26. Bischoff, S.C., and C.A. Dahinden. 1992. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. *Blood* 79:2662-2669.
 27. Burgi, B., U.H. Otten, B. Ochensberger, S. Rihs, K. Heese, P.B. Ehrhard, C.F. Ibanez, and C.A. Dahinden. 1996. Basophil priming by neurotrophic factors. Activation through the trk receptor. *J Immunol* 157:5582-5588.
 28. Virchow, J.C., P. Julius, M. Lommatzsch, W. Luttmann, H. Renz, and A. Braun. 1998. Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. *Am J Respir Crit Care Med* 158:2002-2005.
 29. Lorentz, A., S. Schwengberg, G. Sellge, M.P. Manns, and S.C. Bischoff. 2000. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. *J Immunol* 164:43-48.
 30. Yoshimura, C., M. Yamaguchi, M. Iikura, S. Izumi, K. Kudo, H. Nagase, A. Ishii, A.F. Walls, C. Ra, T. Iwata, T. Igarashi, K. Yamamoto, and K. Hirai. 2002. Activation markers of human basophils: CD69 expression is strongly and preferentially induced by IL-3. *J Allergy Clin Immunol* 109:817-823.
 31. Miura, K., and D.W. MacGlashan, Jr. 2000. Dual phase priming by IL-3 for leukotriene C4 generation in human basophils: difference in characteristics between acute and late priming effects. *J Immunol* 164:3026-3034.
 32. Miura, K., S.S. Saini, G. Gauvreau, and D.W. MacGlashan, Jr. 2001. Differences in functional consequences and signal transduction induced by IL-3, IL-5, and nerve growth factor in human basophils. *J Immunol* 167:2282-2291.
 33. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. *Nat Rev Immunol* 3:361-370.
 34. Wagner, C., C. Iking-Konert, B. Deneffle, S. Stegmaier, F. Hug, and G.M. Hansch. 2004. Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils. *Blood* 103:1099-1104.
 35. Townsend, M.J., P.G. Fallon, D.J. Matthews, H.E. Jolin, and A.N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. *J Exp Med* 191:1069-1076.
 36. Coyle, A.J., C. Lloyd, J. Tian, T. Nguyen, C. Eriksson, L. Wang, P. Ottoson, P. Persson, T. Delaney, S. Lehar, S. Lin, L. Poisson, C. Meisel, T. Kamradt, T. Bjerke, D. Levinson, and J.C. Gutierrez-Ramos. 1999. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. *J Exp Med* 190:895-902.
 37. Lohning, M., A. Stroehmann, A.J. Coyle, J.L. Grogan, S. Lin, J.C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt. 1998. T1/ST2 is

- preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. *Proc Natl Acad Sci U S A* 95:6930-6935.
38. Bischoff, S.C., M. Krieger, T. Brunner, and C.A. Dahinden. 1992. Monocyte chemotactic protein 1 is a potent activator of human basophils. *J Exp Med* 175:1271-1275.
 39. Eglite, S., K. Pluss, and C.A. Dahinden. 2000. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. *J Immunol* 165:2183-2189.
 40. Martinez-Moczygemba, M., and D.P. Huston. 2003. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. *J Allergy Clin Immunol* 112:653-665; quiz 666.
 41. Geijsen, N., L. Koenderman, and P.J. Coffey. 2001. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. *Cytokine Growth Factor Rev* 12:19-25.
 42. Stout, B.A., M.E. Bates, L.Y. Liu, N.N. Farrington, and P.J. Bertics. 2004. IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils. *J Immunol* 173:6409-6417.
 43. Temple, R., E. Allen, J. Fordham, S. Phipps, H.C. Schneider, K. Lindauer, I. Hayes, J. Lockey, K. Pollock, and R. Jupp. 2001. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. *Am J Respir Cell Mol Biol* 25:425-433.
 44. Gong, J.H., G. Maki, and H.G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. *Leukemia* 8:652-658.
 45. Roda-Navarro, P., M. Mittelbrunn, M. Ortega, D. Howie, C. Terhorst, F. Sanchez-Madrid, and E. Fernandez-Ruiz. 2004. Dynamic redistribution of the activating 2B4/SAP complex at the cytotoxic NK cell immune synapse. *J Immunol* 173:3640-3646.
 46. Wills-Karp, M. 2004. Interleukin-13 in asthma pathogenesis. *Immunol Rev* 202:175-190.
 47. Bratke, K., M. Kuepper, B. Bade, J.C. Virchow, Jr., and W. Luttmann. 2005. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8(+) T cell differentiation in peripheral blood. *Eur J Immunol*
 48. Risoan, M.C., T. Duhon, J.M. Bridon, N. Bendriss-Vermare, C. Peronne, B. de Saint Vis, F. Briere, and E.E. Bates. 2002. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. *Blood* 100:3295-3303.
 49. Metkar, S.S., and C.J. Froelich. 2004. Human neutrophils lack granzyme A, granzyme B, and perforin. *Blood* 104:905-906; author reply 907-908.
 50. Grossman, W.J., and T.J. Ley. 2004. Granzymes A and B are not expressed in human neutrophils. *Blood* 104:906-907; author reply 907-908.
 51. Martin, P., R. Wallich, J. Pardo, A. Mullbacher, M. Munder, M. Modolell, and M.M. Simon. 2005. Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes? *Blood* 106:2871-2878.
 52. Wojta, J., C. Kaun, G. Zorn, M. Ghannadan, A.W. Hauswirth, W.R. Sperr, G. Fritsch, D. Printz, B.R. Binder, G. Schatzl, J. Zwirner, G. Maurer, K. Huber, and P. Valent. 2002. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. *Blood* 100:517-523.
 53. Tremblay, G.M., A.M. Wolbink, Y. Cormier, and C.E. Hack. 2000. Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors. *J Immunol* 165:3966-3969.

54. Kemper, C., A.C. Chan, J.M. Green, K.A. Brett, K.M. Murphy, and J.P. Atkinson. 2003. Activation of human CD4⁺ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. *Nature* 421:388-392.
55. Bratke, K., B. Böttcher, K. Leeder, S. Schmidt, M. Küpper J.C. Virchow JR 2004. Increase in granzyme B⁺ lymphocytes and soluble granzyme B in bronchoalveolar lavage of allergen challenged patients with atopic asthma. *Clin Exp Immunol* 136:542-548.
56. Browne, K.A., E. Blink, V.R. Sutton, C.J. Froelich, D.A. Jans, and J.A. Trapani. 1999. Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. *Mol Cell Biol* 19:8604-8615.
57. Gondek, D.C., L.F. Lu, S.A. Quezada, S. Sakaguchi, and R.J. Noelle. 2005. Cutting edge: contact-mediated suppression by CD4⁺CD25⁺ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *J Immunol* 174:1783-1786.
58. Hirst, C.E., M.S. Buzza, V.R. Sutton, J.A. Trapani, K.L. Loveland, and P.I. Bird. 2001. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. *Mol Hum Reprod* 7:1133-1142.
59. Buzza, M.S., L. Zamurs, J. Sun, C.H. Bird, A.I. Smith, J.A. Trapani, C.J. Froelich, E.C. Nice, and P.I. Bird. 2005. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. *J Biol Chem* 280:23549-23558.

Figure legends

Figure 1

IL-3 induces granzyme B expression in human basophils. (A) Dose-dependent induction of granzyme B in basophils stimulated with IL-3. Left, basophils were cultured with different concentrations of unglycosylated E. coli-derived or glycosylated CHO-derived recombinant human IL-3 for 24 hours. The GzmB content was then determined by a specific ELISA in cell lysates. A representative experiment (mean of triplicates) out of three is shown. Right, basophils were cultured without or with different concentrations of IL-3 as indicated for 24 hours. GzmB expression was analyzed in cellular protein extracts by western blotting. Actin is shown as a loading control. The variability of GzmB induction at a maximally effective concentration of IL-3 in basophils isolated from different donors is shown in [supplementary figure 1](#) **(B)** Expression of GzmB by NK cells and human basophils, but not neutrophils. Basophils were cultured in the absence or presence of IL-3 (10 ng/ml) for 20 h. Protein extracts prepared from cultured basophils or freshly isolated neutrophils (N) and NK cells (NK) were analyzed by western blotting using anti-GzmB mAb (left), and anti- α -defensin-1/3 mAb (right). The number of cells corresponding to the protein amount loaded on a gel is indicated above the lines. Actin is shown as a loading control. Results are representative of three independent experiments with cells from different donors. **(C)** Heterogeneous expression of GzmB in basophils. Intracellular expression of GzmB (left) and cell surface expression of ST2 (right) were analyzed by flow cytometry in basophils cultured for 20 h without and with IL-3 (10 ng/ml). **(D)** GzmB staining shows a cytoplasmic granular pattern. Cytospin preparations of basophils cultured for 20 h with IL-3 (10 ng/ml) were stained with anti-GzmB mAb (green, top) or isotype-matched control (mouse IgG1) (green, bottom). DNA was stained with DAPI (blue). Shown are merged images with an original magnification of 60x.

Figure 2

Time course of IL-3-induced expression of granzyme B, and its exocytosis in response to different basophil agonists. (A) Release of granzyme B by degranulation of basophils upon IgE-dependent or IgE-independent stimulation. Purified basophils were cultured in medium alone or exposed to a maximally effective concentration of IL-3 (10 ng/ml) for the indicated time periods and subsequently stimulated with buffer (control), anti-Fc ϵ RI α mAb (100 ng/ml, algER) or C5a (10 nM) for 30 min. Top, GzmB was measured in the cell supernatants and in pellets by ELISA. The entire bars give an estimation of total GzmB for every condition. Bottom, histamine was measured in the supernatants and in the pellets as an indicator of basophil degranulation. A representative experiment (mean of triplicates) is shown. In experiments performed with cells from different donors GzmB released by basophils cultured with IL-3 for 24 hours was on average 1870 pg GzmB/10⁶ basophils (range 1150–4600 pg; 9 donors) upon stimulation with C5a, and 2150 pg GzmB/10⁶ basophils (range 1310–4920 pg; 5 donors) upon IgE-receptor cross-linking. **(B)** Exocytosis of GzmB is induced by diverse agonists. Basophils were cultured with or without IL-3 (10 ng/ml) for 20 h before stimulation with anti-Fc ϵ RI α mAb (100 ng/ml; algER), C5a (10 nM), fMLP (2.5 μ M), MCP-1 (100 nM) or eotaxin (100 nM) for 30 min. Released GzmB, histamine and LTC₄ were measured in the cell supernatants. Mean values of triplicates of a representative experiment are shown. An identical pattern of results with the same order of efficacy of these agonists was observed with cells from 3 different donors.

Figure 3

Continuous granule exocytosis and granzyme B secretion upon simultaneous stimulation of basophils with C5a and IL-3. Shown is a time course of basophil exocytosis, GzmB formation and release, lipid mediator formation and cytokine expression in response to IL-3 and C5a. Basophils were cultured in medium alone, with IL-3 (10 ng/ml), C5a (10 nM) or with the combination of C5a and IL-3 for indicated time periods. C5a was added to the cells at 4°C before culture at 37°C. IL-3 addition followed 30 min later at 37°C. GzmB and the

basophil granule marker histamine were measured in cell supernatants and pellets. LTC₄ formation and cytokine secretion (IL-4 and IL-13) were measured in the cell supernatants only. Mean values of triplicates of a representative experiment (out of three) are shown.

Figure 4

Induction of GzmB by cytokines and products of activated mast cells. (A) Effect of different cytokines on the induction of GzmB and on the response of basophils to C5a. Basophils were cultured overnight in medium alone or with IL-3 (10 ng/ml), GM-CSF (50 ng/ml), IL-5 (50 ng/ml), NGF (50 ng/ml), IL-2 (100 U/ml), IFN- α (1000 U/ml) or IFN- γ (1000 U/ml). Intracellular GzmB was analyzed by flow-cytometry. The Δ mean fluorescence (mean fluorescence of the specific mAb minus fluorescence of control antibody for each condition) is shown. Lower panels: Following overnight culture with indicated cytokines, basophils were stimulated with C5a (10 nM) for 30 min to induce degranulation. Released (black columns) and cell-associated (open columns) GzmB, LTC₄ and histamine release is shown. No histamine or LTC₄ release was detected when the stimulation with C5a was omitted (not shown). Mean values of triplicates of a representative experiment are shown. Experiments performed with basophils from three different donors showed an identical pattern of results and the same order of efficacy of the cytokines. Also note the congruent results for GzmB induction determined by flow-cytometry and ELISA which were performed in independent experiments. **(B)** Relationship between induction of GzmB and “late priming” with different concentrations of IL-3. Basophils were incubated in medium or different concentrations of IL-3. After 24 h cells were stimulated with 10 nM C5a for 30 min. Released and cell-associated GzmB and histamine and leukotriene formation is shown (mean values of triplicate determinations of a representative experiment out of three). **(C)** The products of IgE-activated mast cells induce GzmB in basophils. Western blots of cell extracts of basophils cultured overnight with supernatants of human mast cells (MC supernatants) which have been activated by IgE-receptor cross-linking (α -IgER) or not (buffer) are shown (see Materials and Methods). For comparison, extracts of the same basophil preparation of freshly

isolated basophils, or basophils cultured in medium (buffer) or with IL-3 (10 ng/ml) are included in the blot. Where indicated by (+), a neutralizing polyclonal goat anti-IL-3 antibody (a-IL-3; 10 μ g/ml) was added. An irrelevant control goat IgG had no effect on GzmB expression (data not shown). Tyr694-phosphorylation of Stat5 is shown as another independent indicator for the stimulation of basophils by mast cell-derived IL-3. Total Stat5 levels were identical under all the conditions (data not shown).

Figure 5

Cell-type- restricted expression of GzmB. **(A)** Purified granulocytes, basophils (B), eosinophils (E) and neutrophils (N), were cultured overnight in medium alone or with IL-3 (10 ng/ml), IL-5 (50 ng/ml) and GM-CSF (50 ng/ml) as indicated. The GzmB content in total cell lysates was determined by specific ELISA. Mean values of triplicates of a representative experiment out of three are shown. **(B)** Protein extracts derived from freshly isolated cells or from cells cultured for 24 h in medium alone or with IL-3, IL-5, and GM-CSF (all at 50 ng/ml) were analyzed for GzmB and Pim-1 expression. Actin is shown as a loading control. The data shown in panels A and B were from separate experiments with cells from different donors

Figure 6

Cytotoxic activity of human peripheral blood basophils. **(A)** Non stimulated basophils, IL-3-stimulated (50 ng/ml, 40 h) basophils and NK 92 cells were analyzed in a direct killing assay against [51 Cr]-labeled B-LCL 721.221 cells. Effector cells were incubated for 10 h with target cells at E:T (effector:target) ratios of 15:1, 30:1 and 60:1. **(B)** IL-3-stimulated basophils and NK 92 cells were incubated with B-LCL 721.221 target cells in the absence or presence of Z-VAD-fmk (50 μ M) (pan-caspase inhibitor) or Z-IETD-fmk (50 μ M) (GzmB inhibitor) for 10 h at an E:T ratio of 60:1. Cytotoxicity was estimated as described in Materials and Methods. The data shown (mean of duplicates) are representative of three independent experiments. The enhancement of the cytotoxic activity of basophils by IL-3 and its inhibition

by the pan-caspase- and GzmB-inhibitors were statistically significant ($p > 0.01$ for all conditions as determined by the paired students t-test).

Figure 7

Granzyme B is released in experimental allergic late-phase reaction in asthma patients. Segmental allergen provocation was performed in 13 patients suffering from allergic asthma. Separate lung segments were challenged with saline or antigen and bronchiolar-alveolar lavage (BAL) was performed in the same session 10 min later. 18 h after challenge, a second bronchoscopy was performed and BAL was repeated for recovery of inflammatory mediators. **(A)** Tryptase, IL-13, GzmB and GzmA levels in the BAL-fluids of each of 13 patients analysed are shown. **(B)** Shown are the correlations between tryptase levels of the challenged site in the immediate response (10 minutes) and GzmB levels in the late-phase reactions (18 hours) as well as correlations between IL-13, GzmB and GzmA levels in BAL-fluids of the challenged segment 18 hours after allergen provocation.

Table 1:

Fold change of Granzyme B-mRNA levels in stimulated basophils

Time ^a	medium ^a		IL-3 ^a		α-IgER ^a		IL-5 ^a	
	Exp. 1:	Exp. 2:	Exp. 1:	Exp. 2:	Exp. 1:	Exp. 2:	Exp. 1:	Exp. 2:
0 h	1 ^b	1 ^b						
1 h			8	5				
2 h			355	56				
6 h	73	5	6061	987	481	12	611	10
18 h	33	2	8023	316				
48 h			79	5				

^a Basophils were cultured without (medium) or with IL-3 (20 ng/ml), anti-IgE receptor antibody (α-IgER) (200 ng/ml) or IL-5 (20 ng/ml) for the time period (in hours) indicated. Shown are mean values of duplicates from two separate experiments (Exp. 1; Exp. 2) with basophils purified from different donors.

^b Fold change, mRNA quantity relative to freshly isolated basophils defined as 1.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7





blood[®]

Prepublished online June 22, 2006;
doi:10.1182/blood-2006-03-010348 originally published online
June 22, 2006

Granzyme B, a novel mediator of allergic inflammation: Its induction and release in blood basophils and human asthma

Cornelia M Tschopp, Nicole Spiegl, Svetlana Didichenko, Werner Lutmann, Peter Julius, J C Virchow, C E Hack and Clemens A Dahinden

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.